Aethlon Medical, Inc. (NASDAQ:AEMD) Stock Short Interest Declines 83.8%

Aethlon Medical, Inc. (NASDAQ:AEMD – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 74,846 shares, a decrease of 83.8% from the August 31st total of 461,661 shares. Based on an average daily trading volume, of 184,597 shares, the days-to-cover ratio is presently 0.4 days. Currently, 10.6% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several analysts have commented on AEMD shares. Wall Street Zen upgraded Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. Finally, HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $1.50.

Get Aethlon Medical alerts:

Read Our Latest Stock Report on AEMD

Aethlon Medical Stock Down 7.2%

Shares of NASDAQ AEMD traded down $0.49 during trading on Friday, hitting $6.28. 133,193 shares of the company traded hands, compared to its average volume of 7,249,911. The firm has a market capitalization of $4.46 million, a P/E ratio of -0.18 and a beta of 1.40. The company has a 50-day moving average price of $3.10 and a 200-day moving average price of $7.18. Aethlon Medical has a 1 year low of $1.41 and a 1 year high of $41.35.

Aethlon Medical (NASDAQ:AEMD – Get Free Report) last issued its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share for the quarter, missing the consensus estimate of ($3.92) by ($0.10). Research analysts predict that Aethlon Medical will post -5.74 EPS for the current fiscal year.

Aethlon Medical Company Profile

(Get Free Report)

Aethlon Medical, Inc is a clinical-stage medical device company focused on developing therapeutic technologies for cancer and life-threatening viral infections. The company’s lead product is the Hemopurifier, an investigational extracorporeal blood filtration device designed to selectively remove certain disease-causing particles, including tumor-derived exosomes and viruses, from the bloodstream.

The Hemopurifier is being evaluated as a potential adjunct to existing treatments. In oncology, the technology is intended to remove exosomes that may contribute to tumor progression and immune suppression.

Featured Stories

• Five stocks we like better than Aethlon Medical
• 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
• SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
• These 3 Overlooked Stocks Have Big Money Behind Them
• Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.